A phase i dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1585-1590

  Zhao, Kuai Le ^a   Hu, Xi Chun ^a   Wu, Xiang Hua ^a   Fu, Xiao Long ^a   Fan, Min ^a   Jiang, Guo Liang ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Chemoradiation; Esophageal carcinoma; Nimotuzumab

Indexed keywords

CISPLATIN; FLUOROURACIL; NIMOTUZUMAB;

ABDOMINAL DISCOMFORT; ADULT; ADVANCED CANCER; AGED; AGRANULOCYTOSIS; ANEMIA; ANOREXIA; ARTICLE; CHEMORADIOTHERAPY; CHILL; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAPHORESIS; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS ULCER; FATIGUE; FEMALE; HEMATEMESIS; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; INTENSITY MODULATED RADIATION THERAPY; JAW PAIN; LEUKOCYTURIA; LEUKOPENIA; LIVER INJURY; MALE; MAXIMUM TOLERATED DOSE; MICTURITION DISORDER; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NECK PAIN; NEUTROPENIA; ODYNURIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION DOSE FRACTIONATION; SIDE EFFECT; SKIN MANIFESTATION; THORAX PAIN; THROMBOCYTOPENIA; VOMITING; XEROSTOMIA;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84866737142     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9735-0     Document Type: Article

References (18)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90
2. Mariotto A, Gigli A, Capocaccia R, Tavilla A, Clegg LX, Depry M, Scoppa S, Ries LAG, Rowland JH, Tesauro G, Feuer EJ (2002) SEER cancer statistics review, 1973-1999. Bethesda, MD: National Cancer Institute http://seer.cancer. gov/csr/1973-1999/prevalence.pdf
3. Dragovich T, Campen C (2009) Anti-EGFR-targeted therapy for esophageal and gastric cancers: an evolving concept. JOncol 2009:1-8
4. Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A (2002) Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 101:567-575
5. Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, Nakagawa K (2008) Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 98 (4):749-755
6. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T (2010) Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9(5):343-349
7. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Lyer H, Arvind AS (2009) Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 1 (1):41-48
8. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL (1999) Chemoradiation of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281(17):1623-1627
9. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167-1174
10. You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX (2010) A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies. Invest New Drugs, May 8. [Epub ahead of print]
11. Crombet T, Torres L, Neninger E, Catalá M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Pérez R, Lage A (2003) Pharmacological evaluation of humanized antiepidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother 26(2):139-148
12. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximabinduced rash and survival. Lancet Oncol 11(1):21-28
13. Huang XD, Xu GZ, Gao L (2007) Combined therapy of irradiation and Nimotuzumab for nasopharyngeal carcinoma. Chin J Oncol 29:197-201
14. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, Fernández E, Alvárez D, Torres O, Ramos M, Leonard I, Pérez R, Lage A (2004) Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 22(9):1646-1654
15. Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, Leonard I, Torres O, Marinello P, Pérez R, Lage A (2006) Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3. Cancer Biol Ther 5(4):375-379
16. Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11(4):689-708
17. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R (2011) Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther 11(4):373-382
18. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J (2010) Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 16(8):2474-2482